EQT Agrees a €10.8 Billion Take-Private of Qiagen

EQT has agreed to acquire diagnostics group Qiagen in a transaction valued at €10.8 billion including debt, converting a competitive sale process into one of Europe’s largest take-private agreements of 2026.

Qiagen's management and supervisory boards unanimously support the all-cash offer of €46.50 a share. Reuters calculated an equity value of about €9.6 billion, or $10.8 billion, while the enterprise-value figure includes debt. The offer stands only 8.6% above Qiagen's immediately preceding close, but roughly 40% above the price before takeover reports began moving the shares.

The distinction explains why two premiums can both be accurate. Investors had already priced in a substantial probability of a deal after Qiagen began reviewing strategic options and bids emerged. The clean comparison for judging what EQT is paying is the unaffected price; the comparison with the latest close measures only the remaining spread after speculation.

EQT is investing alongside the Abu Dhabi Investment Authority and Canada Pension Plan Investment Board. Bringing sovereign and pension capital into the consortium reduces the equity burden on one sponsor and reflects the scale of the financing. The transaction still requires shareholder and regulatory approvals, so the announced price is not yet cash in investors' accounts.

Qiagen occupies a valuable part of the life-sciences supply chain. Its sample-preparation, molecular-testing and bioinformatics products are used by clinical laboratories, researchers and pharmaceutical groups. Installed instruments can create recurring demand for consumables, a profile that can support leverage more reliably than a business dependent on one-off equipment sales.

The company has nevertheless faced a difficult reset since the pandemic. Demand for Covid-related testing declined, and weakness in tuberculosis diagnostics contributed to pressure on sales. A failed $11.5 billion approach from Thermo Fisher in 2020 also established a reference point against which current shareholders will judge the new agreement.

Private ownership may give management more freedom to invest through uneven quarters, pursue acquisitions and adjust the portfolio. It also introduces debt-service and return targets. In diagnostics, aggressive cost reduction can damage research, product quality and regulatory compliance, so EQT's operating plan will matter as much as the purchase price.

Competition and foreign-investment authorities will review the buyer group, relevant portfolio overlaps and control of health-related technology. Closing conditions, financing and the offer timetable will determine whether the transaction reaches completion. Until then, shareholders carry deal risk as well as the possibility of a rival intervention.

This is a material follow-up to the database's 20 October report that EQT and KKR were bidding. The new information is the signed agreement, final price, unanimous board recommendation and identified consortium—not a repetition of the earlier talks.

Why it matters

The acquisition demonstrates that sponsors can still finance multibillion-euro healthcare deals despite higher borrowing costs. It may reset valuation expectations for diagnostics and laboratory-technology companies while giving European private equity another large public-to-private transaction.

For employees and customers, the open question is how ownership and leverage change investment. For shareholders, the key issues are approvals, timetable and closing certainty. The deal is agreed, but it is not completed.

Sources: Qiagen investor relations · Reuters · Financial Times